摘要
目的:通过对国内公开发表的中药药物经济学研究性文献进行系统评价和质量评估,了解国内中药药物经济学的研究现状,分析目前研究存在的问题并提出改进建议。方法:制定文献检索策略及纳入排除标准;检索CNKI、VIP、万方和Sinomed四个中文数据库,从建库至2017年1月收录的中药药物经济学研究性文献;提取文献基本信息并进行统计;采用BMJ guidelines对文献进行质量评价。结果:符合纳入标准的中药药物经济学文献共304篇。对发表时间、期刊杂志、作者分布、基金资助、研究疾病、评价药物、研究设计、评价方法、成本测算、产出指标以及不确定性分析情况进行系统分析和质量评分,结果显示文献总体得分为0.59。结论:目前中药药物经济学研究存在缺乏基金支持、质量总体偏低、研究视角不明确、研究设计缺乏依据、成本测算局限及错误、产出指标可比性差等问题。建议制定中药药物经济学评价指南,规范研究路径;建立合理的中药产出指标,增强临床可比性;加强临床和学术合作,提高研究质量。
Objective： To understand the present situation of the researches on the Pharmacoecnomics（PE） of Traditional Chinese Medicine（TCM） in China, analyzes the existing problems and make suggestions for improvement.Methods： To develop a literature search strategy and incorporate exclusion criteria; to retrieved PE researches on TCM from CNKI, VIP, Wanfang and Sinomed database, until January 2017; to extract the basic information of the literatures; to evaluate the quality of the literatures in the light of BMJ guidelines. Results： 304 articles were included. And the information of periodicals and journals, author distribution, fund support, research of diseases and drugs, research design, evaluation methods, cost estimates, output indicators and uncertainty analysis were statistical analyzed. The overall score of the literature quality was 0.59.Conclusion： There are some problems in the existing researches, such as lack of fund support, low overall quality, unclear research perspective, lack of research design basis, cost calculation limitations and errors, poor comparability of output index. We recommend the development of guidelines for the evaluation of PE of TCM to standardize the research path; establish reasonable indicators of TCM output to enhance clinical comparability; strengthen clinical and academic cooperation to improve the quality of research.
出处
《中国研究型医院》
2017年第6期50-58,共9页
Chinese Research Hospitals
关键词
中药
药物经济学
系统评价
质量评价
Traditional Chinese Medicine
Pharmacoeconomics
System review
Quality evaluation
